Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Characterization of inorganic phosphate transport in the triple-negative breast cancer cell line, MDA-MB-231

2018; Public Library of Science; Volume: 13; Issue: 2 Linguagem: Inglês

10.1371/journal.pone.0191270

ISSN

1932-6203

Autores

Thaís Russo-Abrahão, Marco Antonio Lacerda‐Abreu, Tainá Gomes, Daniela Cosentino-Gomes, Ayra Diandra Carvalho-de-Araújo, Mariana Figueiredo Rodrigues, Ana Carolina Leal de Oliveira, Franklin David Rumjanek, Robson Q. Monteiro, José Roberto Meyer‐Fernandes,

Tópico(s)

Genetic Syndromes and Imprinting

Resumo

Background Recent studies demonstrate that interstitial inorganic phosphate is significantly elevated in the breast cancer microenvironment as compared to normal tissue. In addition it has been shown that breast cancer cells express high levels of the NaPi-IIb carrier (SLC34A2), suggesting that this carrier may play a role in breast cancer progression. However, the biochemical behavior of inorganic phosphate (Pi) transporter in this cancer type remains elusive. Methods In this work, we characterize the kinetic parameters of Pi transport in the aggressive human breast cancer cell line, MDA-MB-231, and correlated Pi transport with cell migration and adhesion. Results We determined the influence of sodium concentration, pH, metabolic inhibitors, as well as the affinity for inorganic phosphate in Pi transport. We observed that the inorganic phosphate is dependent on sodium transport (K0,5 value = 21.98 mM for NaCl). Furthermore, the transport is modulated by different pH values and increasing concentrations of Pi, following the Michaelis-Menten kinetics (K0,5 = 0.08 mM Pi). PFA, monensin, furosemide and ouabain inhibited Pi transport, cell migration and adhesion. Conclusions Taken together, these results showed that the uptake of Pi in MDA-MB-231 cells is modulated by sodium and by regulatory mechanisms of intracellular sodium gradient. General Significance: Pi transport might be regarded as a potential target for therapy against tumor progression.

Referência(s)